Elimination of senescent neutrophils by TNF-related apopotosis-inducing ligand

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 1232-1238

  Lum, Julian J ^a   Bren, Gary ^a   McClure, Rebecca ^a   Badley, Andrew D ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR4; DEATH RECEPTOR; PROTEIN INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CELL AGING; CHEMOTAXIS; CONTROLLED STUDY; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PHAGOCYTE; PRIORITY JOURNAL; SENESCENT NEUTROPHIL;

EID: 23244440014     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.1232     Document Type: Article

References (42)

1. Simon, H. U. 2003. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol. Rev. 193: 101-110.
2. Akgul, C., D. A. Moulding, and S. W. Edwards. 2001. Molecular control of neutrophil apoptosis. FEBS Lett. 487: 318-322.
3. Hotta, K., M. Niwa, A. Hara, T. Ohno, X. Wang, H. Matsuno, O. Kozawa, H. Ito, K. Kato, T. Otsuka, N. Matsui, and T. Uematsu. 2001. The loss of susceptibility to apoptosis in exudated tissue neutrophils is associated with their nuclear factor-κB activation. Eur. J. Pharmacol. 433: 17-27.
4. Brach, M. A., S. deVos, H. J. Gruss, and F. Herrmann. 1992. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 80: 2920-2924.
5. Lee, A., M. K. Whyte, and C. Haslett. 1993. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J. Leukocyte Biol. 54: 283-288.
6. Scheel-Toellner, D., K. Wang, N. V. Henriquez, P. R. Webb, R. Craddock, D. Pilling, A. N. Akbar, M. Salmon, and J. M. Lord. 2002. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. Eur. J. Immunol. 32: 486-493.
7. Wang, K., D. Scheel-Toellner, S. H. Wong, R. Craddock, J. Caamano, A. N. Akbar, M. Salmon, and J. M. Lord. 2003. Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-δ, and NF-κB signaling pathways. J. Immunol. 171: 1035-1041.
8. Le'Negrate, G., P. Rostagno, P. Auberger, B. Rossi, and P. Hofman. 2003. Down-regulation of caspases and Fas ligand expression, and increased life span of neutrophils after transmigration across intestinal epithelium. Cell Death Differ. 10: 153-162.
9. Haslett, C. 1999. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med. 160: S5-S11.
10. 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5: 653-666.
11. Kobayashi, S. D., J, M. Voyich, C. L. Buhl, R. M. Stahl, and F. R. DeLeo. 2002. Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocylosis: cell fate is regulated at the level of gene expression. Proc. Natl. Acad. Sci. USA 99: 6901-6906.
12. Zhang, B., J. Hirahashi, X. Cullere, and T. N. Mayadas. 2003. Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis: crosstalk between caspase 8, reactive oxygen species, and MAPK/ERK activation. J. Biol. Chem. 278: 28443-28454.
13. Martin, C., P. C. Burdon, G. Bridger, J. C. Gutierrez-Ramos, T. J. Williams, and S. M. Rankin, 2003. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 19: 583-593.
14. Juarez, J., and L, Bendall. 2004. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol. Histopathol. 19: 299-309.
15. Liles, W. C., P. A. Kiener, J. A. Ledbetter, A. Aruffo, and S. J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184: 429-440.
16. Murray, J., J. A. Barbara, S. A. Dunkley, A. F. Lopez, X. Van Ostade, A. M. Condliffe, I. Dransneld, C. Haslett, and E. R. Chilvers. 1997. Regulation of neutrophil apoptosis by tumor necrosis factor-α: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 90: 2772-2783.
17. Renshaw, S. A., J. S. Parmar, V. Singleton, S. J. Rowe, D. H. Dockrell, S. K. Dower, C. D. Bingle, E. R. Chilvers, and M. K. Whyte. 2003. Acceleration of human neutrophil apoptosis by TRAIL. J. Immunol. 170: 1027-1033.
18. Seino, K., K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161: 4484-4488.
19. Ottonello, L., G. Tortolina, M. Amelotti, and F. Dallegri. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162: 3601-3606.
20. Nagase, H., M. Miyamasu, M. Yamaguchi, M. Imanishi, N. H. Tsuno, K. Matsushima, K. Yamamoto, Y. Morita, and K. Hirai. 2002. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J. Leukocyte Biol. 71:711-717.
21. Patel, L., S. J. Charlton, J. K. Chambers, and C. H. Macphee. 2001. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine 14: 27-36.
22. Li, J. H., N. C. Kirkiles-Smith, J. M. McNiff, and J. S. Pober. 2003. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 171: 1526-1533.
23. Lamhamedi-Cherradi, S. E., S. Zheng, R. M. Tisch, and Y. H. Chen. 2003. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type I diabetes. Diabetes 52: 2274-2278.
24. Hilliard, B., A. Wilmen, C. Seidel, T. S. Liu, R. Coke, and Y. Chen. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166: 1314-1319.
25. Song, K., Y. Chen, R. Coke, A. Wilmen, C. Seidel, A. Goke, and B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp. Med. 191: 1095-1104.
26. -/- mice. Nat. Immunol. 4: 255-260.
27. Weaver, J. G. R., M. S. Rouse, J. M. Steckelberg, and A. D. Badley. 2004. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 18: 1185-1191.
28. Daigle, I., and H. U. Simon. 2001. Alternative functions for TRAIL receptors in eosinophils and neutrophils. Swiss Med. Wkly. 131: 231-237.
29. Livak, F., S. C. Welsh, C. J. Guidos, I. N. Crispe, J. S. Danska, and D. G. Schatz. 1996. Transient restoration of gene rearrangement at multiple T cell receptor loci in γ-irradiated seid mice. J. Exp. Med. 184: 419-428.
30. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7: 821-830.
31. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386-5397.
32. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113.
33. Marsters, S. A., J. P. Sheridan, R. M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A. D. Goddard, P. Godowski, and A. Ashkenazi. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7: 1003-1006.
34. Emery, J. G., P. McDonnell, M. B. Burke, K. C. Deen, S. Lyn, C. Silverman, E. Dul, E. R. Appelbaum, C. Eichman, R. DiPrinzio, et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363-14367.
35. Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, and T. Zhou. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7: 954-960.
36. Matsumura, R., K. Umemiya, M. Kagami, H. Tomioka, E. Tanabe, T. Sugiyama, M. Sueishi, N. Kayagaki, H. Yagita, and K. Okumura. 2002. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome. Clin. Exp. Rheumatol. 20: 791-798.
37. Zeise, E., M. Weichemhal, T. Schwarz, and D. Kulms. 2004. Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP. J. Invest. Dermatol. 123: 746-754.
38. L expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64: 7086-7091.
39. Wang, S., and W. S. El-Deiry. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.
40. Mundt, B., F. Kuhnel, L. Zender, Y. Paul, H. Tillmann, C. Trautwein, M. P. Manns, and S. Kubicka. 2003. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17: 94-96.
41. Bretz, J. D., E. Mezosi, T. J. Giordano, P. G. Gauger, N. W. Thompson, and J. R. Baker. Jr. 2002. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ. 9: 274-286.
42. Lum, J. J., D. J. Schnepple, and A. D. Badley, 2005. Acquired T cell sensitivity to TRAIL-mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. AIDS. In press.